Novo Nordisk announced that the Food and Drug Administration (FDA) has approved a new 30mg/3.0mL strength of Norditropin (somatropin [rDNA origin] injection) FlexPro pen. Somatotropin binds to a ...
The FDA has approved somatropin pre-filled injection pens for the treatment of children and adults with growth hormone disorders. Norditropin FlexPro (Novo Nordisk) has a user-friendly design and an ...
PLAINSBORO, N.J., July 16, 2015 /PRNewswire/ -- Novo Nordisk announced today the U.S. Food and Drug Administration (FDA) approval of FlexPro® PenMate®, designed for users of Norditropin® FlexPro® 5 mg ...
COPENHAGEN, March 3 (Reuters) - The U.S. Food and Drug Administration has approved Danish drugmaker Novo Nordisk's growth hormone injection pen Norditropin Flexpro, the company said on Wednesday.
March 5, 2010 — The US Food and Drug Administration (FDA) has approved a prefilled somatropin (rDNA origin) injection pen (Norditropin FlexPro, Novo Nordisk, Inc) for the treatment of growth hormone ...
COPENHAGEN (Reuters) - The PenMate injection device for use with Novo Nordisk's Norditropin Flexpro treatment for growth hormone-related disorders has been approved by the U.S. Food and Drug ...
Norditropin's injection pen slides inside the new FlexPro PenMate so that its needle is hidden during the injection.--Courtesy of Novo Nordisk Novo Nordisk ($NVO ...
NORDITROPIN NORDIFLEX PEN (Somatropin) 30mg/3mL injection by Novo Nordisk The Norditropin (somatropin [rDNA origin] injection) NordiFlex 30mg/3mL prefilled pen has been made available by Novo Nordisk.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback